The development of a new vaccine was initiated at the request of one of the largest Russian meat companies based on a strain revealed at the company’s premises. The new drug has already undergone preclinical tests.
“According to the research studies, the vaccine proved to be as effective as foreign-made alternatives in stabilizing the safety and productivity of the immunized animals”, says the statement.
The next step in large-scale clinical trials is scheduled for the live dried cell culture-based vaccine against porcine reproductive and respiratory syndrome based on the most relevant strain, PRRSV-1 (European type).
